

1 **Age-Specific Changes in Virulence Associated with SARS-CoV-2 Variants of Concern**

2

3 David N. Fisman¹ MD MPH and Ashleigh R. Tuite^{1,2} PhD MPH

4

5 ¹Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

6 ²Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada

7

8

9 **Address reprint requests and correspondence to:**

10 David Fisman, MD MPH FRCP(C)

11 Room 686, 155 College Street, Toronto, Ontario, M5T 3M7

12 Email: david.fisman@utoronto.ca

13

14 Funding statement: The research was supported by a grant to DNF from the Canadians Institutes
15 for Health Research (2019 COVID-19 rapid researching funding OV4-170360).

16

17 Declaration of competing interests: DNF has served on advisory boards related to influenza and
18 SARS-CoV-2 vaccines for Seqirus, Pfizer, Astrazeneca and Sanofi-Pasteur Vaccines, and has
19 served as a legal expert on issues related to COVID-19 epidemiology for the Elementary
20 Teachers Federation of Ontario and the Registered Nurses Association of Ontario. ART was
21 employed by the Public Health Agency of Canada when the research was conducted. The work
22 does not represent the views of the Public Health Agency of Canada.

23

24 **Abstract**

25

26 **Background:** Novel variants of concern (VOCs) have been associated with both increased
27 infectivity and virulence of SARS-CoV-2. The virulence of SARS-CoV-2 is closely linked to
28 age. Whether relative increases in virulence of novel VOCs is similar across the age spectrum, or
29 is limited to some age groups, is unknown.

30 **Methods:** We created a retrospective cohort of people in Ontario, Canada testing positive for
31 SARS-CoV-2 and screened for VOCs, with dates of test report between February 7 and August
32 30, 2021 (n=233,799). Cases were classified as N501Y-positive VOC, probable Delta VOC, or
33 VOC undetected. We constructed age-specific logistic regression models to evaluate the effects
34 of N501Y-positive or Delta VOC infections on infection severity, using hospitalization, intensive
35 care unit (ICU) admission, and death as outcome variables. Models were adjusted for sex, time,
36 health unit, vaccination status, comorbidities, immune compromise, long-term care residence,
37 healthcare worker status, and pregnancy.

38 **Results:** Infection with either N501Y-positive or Delta VOCs was associated with significant
39 elevations in risk of hospitalization, ICU admission, and death in younger and older adults,
40 compared to infections where a VOC was not detected. Delta VOC increased hospitalization risk
41 in children under 10 by a factor of 2.5 (adjusted odds ratio, 95% confidence interval: 1.2 to 5.1)
42 compared to non-VOC. For most VOC-outcome combinations there was no heterogeneity in
43 adverse outcomes by age. However, there was an inverse relationship between age and relative
44 increase in risk of death with delta VOC, with younger age groups showing a greater relative
45 increase in risk of death than older individuals.

46 **Interpretation:** SARS-CoV-2 VOCs appear to be associated with increased relative virulence of
47 infection in all age groups, though low absolute numbers of outcomes in younger individuals
48 make estimates in these groups imprecise.
49

50 **Introduction**

51

52 Emerging SARS-CoV-2 variants of concern (VOC) have displayed increased infectivity as well
53 as increased virulence relative to strains circulating early in the pandemic (1-7). In particular, the
54 emergence of the highly infectious and virulent Delta variant has led to revised expectations of
55 the pandemic's severity and duration (8-11). Notwithstanding the severe health and economic
56 toll the SARS-CoV-2 pandemic has taken worldwide, one relatively assuasive aspect of its
57 epidemiology had been decreased virulence of infection in children, with nearly 50% of infected
58 children experiencing asymptomatic infection (12, 13). However, in the summer of 2021, both
59 the United Kingdom and the United States have reported an extraordinary surge in pediatric
60 hospitalizations related to SARS-CoV-2 infection (14-17). The coincidence of this surge with
61 Delta variant emergence in both countries has led some to suggest that this surge was driven by
62 Delta variant emergence. However, surging admissions could simply reflect the increased
63 infectivity of Delta variant, resulting in larger numbers of infected children without any change
64 in per-infection virulence. As such, it has been challenging to determine with certainty whether
65 infection with Delta VOC is more virulent in children than non-VOC SARS-CoV-2, or other
66 VOCs, such as those with the N501Y mutation (18).

67

68 Indeed, heterogeneity in the effects of VOC by age, more generally, would be of importance for
69 understanding the likely impacts of future pandemic waves, as well as the epidemiology of
70 SARS-CoV-2 in the post-pandemic era. In the Canadian province of Ontario, VOC carrying the
71 N501Y mutation (including the Alpha/B.1.1.7, Beta/B.1.351 and Gamma /P.1 VOC) replaced
72 earlier SARS-CoV-2 lineages by April 2021, but were, in turn, replaced by the Delta (B.1.617.2)
73 variant, which has been the dominant variant in the province since July 2021 (19, 20). The

74 availability of a single master line list of all COVID-19 cases in the Canadian province of
75 Ontario, which includes patient outcomes (hospitalization, intensive care admission, and/or
76 death), important covariates including underlying medical conditions, and virological typing data
77 from February 2021 forward, provides an opportunity to evaluate age-specific risk associated
78 with VOC infection, and to determine whether there is heterogeneity in virulence across age
79 groups. Our objectives were to: (i) estimate age-specific risks of severe illness in individuals
80 infected with Delta or N501Y-positive VOC, relative to non-VOC SARS-CoV-2 infection; (ii) to
81 evaluate whether there is heterogeneity in differential risk by age group; and (iii) to explore the
82 sources of any such heterogeneity.
83

84 **Methods**

85

86 *Data Sources*

87 We used Ontario's Case and Contact Management (CCM) database to create a retrospective
88 cohort of SARS-CoV-2 cases who underwent screening for variants of concern, and had test
89 report dates between February 7 and September 13, 2021 (as routine screening for N501Y and
90 E484K mutations began on February 7, 2021). Case information, including long term care
91 residence, demographics, underlying medical conditions, and outcomes including hospitalization,
92 ICU admission and death, is available in CCM (21). Case vaccination status, including dates of
93 first and second doses of SARS-CoV-2 vaccines were obtained from COVaxON, Ontario's
94 centralized COVID-19 vaccine database. Individuals were considered partially vaccinated if 14
95 or more days had elapsed between the first vaccine dose and test date; and considered fully
96 vaccinated if the case episode date occurred 7 or more days after receipt of the second dose, and
97 otherwise were considered unvaccinated (22, 23).

98

99 There has been an evolution in VOC screening and viral sequencing in Ontario over the course
100 of the pandemic. VOC cases were initially identified in Ontario in December 2020, with
101 subsequent targeted screening of isolates from individuals with a history suggestive of possible
102 VOC infection (e.g., travel). Systematic screening for VOCs with low cycle threshold (≤ 35)
103 began in February 2021. Initial screening focussed on the N501Y mutation, with screening for
104 both N501Y and E484K initiated in March 2020. At that time a 5% sampling of specimens was
105 subjected to all specimens, regardless of screen results, was initiated, with the fraction increased
106 to 50% by late May 2021. As of June 2021, routine WGS was discontinued on N501Y-
107 POSITIVE/E484- specimens, which were presumed to be alpha lineage. Over 90% of infections

108 were positive for the N501Y mutation as of April 2021, but that fraction decreased subsequently
109 with emergence of Delta variant, which represented over 60% of all infections by July 2021 (19,
110 20).

111

112 We excluded cases if VOC screening information was unavailable or screening had not been
113 performed (N = 50,508). The dataset was extracted on September 14, 2021, with the most recent
114 test report date of September 13, 2021. However, we limited our analysis to cases with a test
115 report date at least 14 days prior (August 30, 2021) to account for delays between testing and
116 occurrence of hospitalization, ICU admission, and death.

117

118 *Analysis*

119 We constructed age-group-specific logistic regression models for the effects of N501Y-positive
120 or Delta VOC infection, on infection severity, defined as hospitalization, ICU admission, or
121 death. Models were adjusted for male sex, time (modeled as a week-on-week linear trend),
122 vaccination status (in age groups 10 years and older), documented major comorbidity (including
123 asthma, COPD, hematological disease, liver disease, cardiac disease, diabetes, renal disease,
124 neurological disease, malignancy, or obesity), and immune compromise. In relevant age groups
125 we also adjusted for pregnancy, long-term care residence and healthcare worker status. Due to
126 geographic variation in timing of emergence of variants, we also adjusted for health unit region,
127 with health units classified as “Greater Toronto-Hamilton Area”, “Ottawa”, and “other”.
128 All of these covariates were expected *a priori* to confound the association between VOC
129 exposure and disease severity. We considered odds ratios to approximate relative risks under the
130 “rare disease assumption” (24).

131 Adjusted odds ratios and confidence intervals for relative severity of VOC from age-
132 group-specific models were incorporated into random effects meta-analyses to generate summary
133 estimates of effect, and to evaluate heterogeneity in effects by variant and age. Heterogeneity by
134 age was assessed by constructing meta-regression models in which age group was treated as an
135 ordinal variable in order to identify linear trends in effect across age groups.

136 We conducted regression analyses in R version 4.1.0; meta-analyses and meta-regression
137 were performed using the meta package in R (25, 26). The study was conducted in accordance
138 with the STROBE guidelines for observational research (27), and received ethics approval from
139 the Research Ethics Board at the University of Toronto.

140

141

142 **Results**

143

144 We included 233,799 cases in our analysis, with episode dates between February 7 and August
145 30, 2021. Among all reported cases, 71.7% were infections with N501Y-positive VOC; 7.6%
146 were classified as probable Delta infections. There were significant differences in hospitalization
147 and ICU admission according to VOC status (**Table 1**). Individuals with VOC were significantly
148 younger, less likely to have comorbidities, and less likely to have reported immune compromise
149 than individuals without VOC. Significant differences were also seen in healthcare worker status,
150 long-term care residence, and geographic location by VOC status. Cases infected with Delta
151 were more likely to be fully vaccinated, reflecting the fact that Delta became established in the
152 population in the spring of 2020, once vaccination programs were underway.

153

154 Adjusted odds ratios for hospitalization, intensive care admission, and death, by age category and
155 VOC, are presented in **Figure 1**. N501Y-positive VOC infection was associated with a
156 significant increase in hospitalization among people aged 20 and over, relative to infection with
157 non-VOC SARS-CoV-2 strains. ICU admission risk was increased in all groups aged 40 and
158 over. Risk of death was significantly elevated in the 20-39 year age group and people aged 60
159 and over. For N501Y-positive VOC, odds ratios could not be estimated for ICU admission in
160 children under 10, or for death in those aged less than 20, due to the rarity of these outcomes.

161

162 For Delta VOC infections, significantly elevated hospitalization risk was seen in all age groups
163 except 10-to-19 year-olds. In children, the risk of hospitalization with Delta VOC was 2.5-fold
164 higher than that seen with non-VOC SARS-CoV-2. ICU admission risk could not be estimated

165 for Delta VOC in children, and elevations in risk among people under 40 years of age were not
166 statistically significant. For people aged 40 and over, marked increases in risk were observed.
167 Odds ratios for death with Delta could not be estimated for those aged less than 30 years; in
168 adults aged greater than 30 years the risk of death was elevated with Delta VOC infection though
169 confidence intervals for estimates in the 50-to-59 year and 80-and-over age groups overlapped 1.
170

171 In random effects meta-analyses, we found no significant heterogeneity in odds ratios across age
172 groups for death and ICU risk with N501Y-positive VOC, or for hospitalization and ICU risk
173 with Delta VOC. By contrast, significant heterogeneity in risk estimates was seen for
174 hospitalization risk across age groups with N501Y-positive VOC, and for death risk with Delta
175 VOC (**Figure 1**). Across all outcomes, infection with Delta VOC was associated with elevated
176 risk, compared to N501Y-positive infections.

177
178 We evaluated the contribution of age to heterogeneity in estimates by constructing meta-
179 regression models with age group treated as a 9-level ordinal variable. For hospitalization risk
180 and N501Y-positive VOC, we found no relationship between age and odds ratio (relative OR per
181 10-year increase in age 1.01, 95% CI 0.97 to 1.05). For mortality risk and Delta VOC, there was
182 an inverse association between age group and relative OR (0.69, 95% CI 0.50 to 0.94).

183

184

185 **Discussion**

186

187 The landscape of SARS-CoV-2 infection continues to change rapidly, with novel variants of
188 concern impacting both transmissibility and virulence of infection. In this analysis, we evaluated
189 the relative impact of earlier N501Y-positive VOC, and subsequent Delta VOC infections on
190 severity of infection by age group. We find that, as reported previously, Delta VOC infection is
191 more virulent than infection with both N501Y-positive VOC and non-VOC SARS-CoV-2 strains
192 (7, 10, 28). We find no statistical evidence that the increase in virulence of Delta VOC in the
193 population as a whole is diminished in younger people. The absence of significant elevations of
194 risk in younger age groups for some outcomes is likely to reflect lower absolute risk (and
195 numbers of events) in these groups, with consequent lack of precision in estimates. Notably, the
196 risk of hospitalization with Delta VOC appears significantly increased in children. The relative
197 rarity of ICU admissions and deaths in younger age groups makes us unable to generate relative
198 risk estimates for these outcomes with Delta in children, but an increase in virulence as well as
199 transmissibility with Delta VOC in children would be consistent with recent observed surges in
200 pediatric hospitalizations reported in the United States and United Kingdom (14-17).

201

202 For most combinations of VOC and outcomes, we found no evidence of variation in increased
203 risk by age, but for Delta VOC, we also found an inverse, age-related gradient in *relative* risk of
204 death with Delta infection with VOC, in contrast to non-VOC infection. This does not indicate
205 that there is no excess risk associated with VOC in older individuals; indeed, we find significant
206 increases in risk of severe outcomes with both N501Y-positive and Delta VOC in older
207 individuals. Rather, this signifies that relative increase in mortality risk with Delta increases as

208 age diminishes for Delta VOC, though our analysis was limited to age groups 40 and older. If
209 this effect proves generalizable, it suggests that the Delta variant will enhance mortality of
210 SARS-CoV-2 infection in younger age groups, which have been (and remain) less likely to
211 experience critical illness than older age groups.

212

213 Our analysis is subject to important limitations: first, the relative rarity of severe outcomes in
214 younger age groups means that our estimates for these groups are imprecise. Furthermore, our
215 failure to identify heterogeneity in severity by age, when evaluating effects in children and teens,
216 may simply be related to the imprecision of estimates in these age groups, rather than true lack of
217 heterogeneity. A second limitation is the degree to which frequency of testing, particularly in
218 younger age groups, has been dynamic in Ontario during the COVID-19 pandemic (21).

219 Increasing frequency of testing in under-tested younger age groups over time, as VOC emerged
220 in the population, could increase the fraction of mild cases identified, and may have served to
221 mask increases in severity.

222

223 In summary, however, we find no evidence to suggest that the apparent increase in virulence of
224 SARS-CoV-2 VOC is limited to a particular age group; indeed, we present evidence that the
225 relative virulence of Delta VOC, as represented by mortality risk, may be inversely related to
226 age. The relative rarity of severe outcomes in children and teens means that more study is needed
227 to assess the robustness and generalizability of these findings.

228

229 **Acknowledgements**

230 We thank the staff at Public Health Ontario and Ontario’s public health units, and Ontario
231 Health, for collecting, sequencing, analyzing, and providing access to the data used for this
232 analysis.

Table 1. Characteristics of study cohort with test date between 7 February and 30 August 2021, by variant of concern (VOC) status.

Descriptor	All	VOC Not Detected	N501Y-positive VOC	Probable Delta	
				VOC	P-value
Total Cases	233,799	48,441	167,575	17,783	
Hospitalized (%)	12,284 (5.3)	2,182 (4.5)	9,093 (5.4)	1,009 (5.7)	<0.001
Admitted to ICU	2627 (1.1)	386 (0.8)	1,974 (1.2)	267 (1.5)	< 0.001
Died	2,148 (0.9)	449 (0.9)	1,552 (0.9)	147 (0.8)	0.41
Male (%)	118,385 (50.6)	24,452 (50.5)	84,849 (50.6)	9,084 (51.1)	0.39
Age (years)					<0.001
Under 10	17,397 (7.4)	3,550 (7.3)	12,155 (7.3)	1,692 (9.5)	
10-19	28,081 (12)	5,842 (12.1)	19,979 (11.9)	2,260 (12.7)	
20-29	49,134 (21)	9,813 (20.3)	34,738 (20.7)	4,583 (25.8)	
30-39	40,152 (17.2)	8,089 (16.7)	28,731 (17.1)	3,332 (18.7)	
40-49	34,382 (14.7)	6,772 (14)	25,381 (15.1)	2,229 (12.5)	
50-59	31,958 (13.7)	6,752 (13.9)	23,363 (13.9)	1,843 (10.4)	
60-69	19,356 (8.3)	4,288 (8.9)	13,954 (8.3)	1,114 (6.3)	
70-79	8,561 (3.7)	2,043 (4.2)	6,083 (3.6)	435 (2.4)	
≥80	4,778 (2)	1,292 (2.7)	3,191 (1.9)	295 (1.7)	

Vaccination status*					< 0.001
Unvaccinated	94,468 (40.4)	18,377 (37.9)	65,191 (38.9)	10,900 (61.3)	
Partially vaccinated	135,578 (58)	29,187 (60.3)	101,452 (60.5)	4,939 (27.8)	
Fully vaccinated	3,753 (1.6)	877 (1.8)	932 (0.6)	1,944 (10.9)	
Comorbidity†	11,448 (4.9)	3,037 (6.3)	7,508 (4.5)	903 (5.1)	< 0.001
Immune compromise	1,816 (0.8)	436 (0.9)	1,235 (0.7)	145 (0.8)	0.0012
Long-term care resident	424 (0.2)	142 (0.3)	205 (0.1)	77 (0.4)	< 0.001
Healthcare worker	3,991 (1.7)	1,081 (2.2)	2,592 (1.5)	318 (1.8)	< 0.001
Pregnancy	646 (0.3)	141 (0.3)	435 (0.3)	70 (0.4)	0.0042
Geography					<0.001
GTHA‡	167,088 (71.5)	30,198 (62.3)	126,118 (75.3)	10,772 (60.6)	
Ottawa	9,783 (4.2)	2,006 (4.1)	7,423 (4.4)	354 (2)	

NOTE: ICU, intensive care unit; VOC, variant of concern; P-values based on chi-squared test.

*Vaccination status is defined as in methods.

†Comorbidities include one or more of asthma, COPD, hematological disease, liver disease, cardiac disease, diabetes, renal disease, neurological disease, malignancy, or obesity. Immune compromise was included as a separate covariate in models.

‡GTHA, Greater Toronto Area and Hamilton, large conurbation in Central Ontario consisting of 6 health units (Toronto, Peel, Durham, Halton, York and Hamilton).

Table 2. Meta-regression derived age-related relative change in odds ratio associated with N501Y-positive and probable Delta variants of concern.

Variant	Outcome	Relative Odds Ratio	95% Confidence Interval	τ^{2*}	R^{2**} (%)
Probable Delta					
	Hospitalization	1.00	0.93-1.07	0.0178	0
	ICU admission	1.07	0.93-1.22	0	0
	Death	0.69	0.50-0.94	0.1647	45.84
N501Y-positive					
	Hospitalization	1.01	0.97-1.05	0.0115	0
	ICU admission	1.01	0.94-1.09	0	0
	Death	0.94	0.83-1.06	0.0166	12.68


NOTE: Linear trend estimated by treating age category as a 9-level ordinal variable.

*Estimated amount of residual heterogeneity due to between-age group variation.

*Fraction of heterogeneity accounted for by including age in meta-regression models.

Figure 1. Forest plot with adjusted odds ratios for hospitalization, intensive care unit admission, and death by age group and SARS-CoV-2 variant of concern.

Models were adjusted for sex, health unit region, age group, vaccination status, comorbidity, immune compromise, and (in relevant age groups) long-term care residence, healthcare worker status, and pregnancy.



References

1. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021;372(6538).
2. Brown KA, Joh E, Buchan SA, Daneman N, Mishra S, Patel S, et al. Inflection in prevalence of SARS-CoV-2 infections missing the N501Y mutation as a marker of rapid Delta (B.1.617.2) lineage expansion in Ontario, Canada. *medRxiv*. 2021:2021.06.22.21259349.
3. Brown KA, Gubbay J, Hopkins J, Patel S, Buchan SA, Daneman N, et al. Rapid Rise of S-Gene Target Failure and the UK variant B.1.1.7 among COVID-19 isolates in the Greater Toronto Area, Canada. *medRxiv*. 2021:2021.02.09.21251225.
4. Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. *BMJ*. 2021;373:n1412.
5. Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis*. 2021.
6. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. *Euro Surveill*. 2021;26(16).
7. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*. 2021;397(10293):2461-2.

8. Nunes-Vaz R, Macintyre CR. Observations on the current outbreak of the SARS-CoV-2 Delta Variant in Sydney. Available via the Internet at <http://doi.org/10.31646/gbio.121>, last accessed September 1, 2021. *Global Biosecurity*. 2021;3(1).
9. Scudellari M. How the coronavirus infects cells - and why Delta is so dangerous. *Nature*. 2021;595(7869):640-4.
10. Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh M, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). *Clin Infect Dis*. 2021.
11. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. *medRxiv*. 2021:2021.07.05.21260050.
12. Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *Proc Natl Acad Sci U S A*. 2021;118(34).
13. Herrera-Esposito D, de los Campos G. Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. *medRxiv*. 2021:2021.07.29.21261282.
14. Borter G. Children hospitalized with COVID-19 in U.S. hits record number. 4 minute read. Available via the Internet at <https://www.reuters.com/world/us/children-hospitalized-with-covid-19-us-hits-record-number-2021-08-14/>. Last accessed September 3, 2021.: Reuters.; 2021.
15. American Academy of Pediatrics. Children and COVID-19: State-Level Data Report. Available via the Internet at <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/>. Last accessed September 3, 2021. 2021.

16. Anthes E. The Delta Variant Is Sending More Children to the Hospital. Are They Sicker, Too? Available via the Internet at <https://www.nytimes.com/2021/08/09/health/coronavirus-children-delta.html>. Last accessed September 2, 2021. New York Times. 2021 August 9, 2021.
17. Roucaute D, Santi P, Hecketsweiler C. Le variant Delta provoque des craintes pour la rentrée scolaire. Available via the Internet at https://www.lemonde.fr/planete/article/2021/08/26/variant-delta-inquietudes-autour-d-une-rentree-scolaire-a-risque_6092366_3244.html. Last accessed September 2, 2021. Le Monde. 2021 August 26, 2021.
18. Tuite AR, Fisman DN, Oduyayo A, Bobos P, Allen V, Bogoch I, et al. COVID-19 hospitalizations, ICU admissions and deaths associated with the new variants of concern. Accessed 5 Jul 2021: <https://doi.org/10.47326/ocsat.2021.02.18.1.0>. 2021.
19. Public Health Ontario. Epidemiologic summary: SARS-CoV-2 whole genome sequencing in Ontario, June 30, 2021. Accessed 5 Jul 2021: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-sars-cov2-whole-genome-sequencing-epi-summary.pdf?sc_lang=en. 2021.
20. Public Health Ontario. Epidemiologic summary: Estimating the prevalence and growth of SARS-CoV-2 variants in Ontario using mutation profiles. Accessed 5 Jul 2021: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-prevalence-growth-voc-mutation-epi-summary.pdf?sc_lang=en. 2021.
21. Fisman DN, Greer AL, Brankston G, Hillmer M, O'Brien SF, Drews SJ, et al. COVID-19 Case Age Distribution: Correction for Differential Testing by Age. *Ann Intern Med*. 2021.
22. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2

infection and severe COVID-19 outcomes in Ontario, Canada. medRxiv.

2021:2021.05.24.21257744.

23. Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. medRxiv. 2021:2021.06.28.21259420.

24. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. *Am J Epidemiol*. 1982;116(3):547-53.

25. R Core Team. R: A language and environment for statistical computing. Available via the Internet at <https://www.R-project.org/>. Last accessed September 24, 2021. Vienna, Austria.: R Foundation for Statistical Computing; 2017.

26. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evidence-Based Mental Health*. 2019;22(4):153–60.

27. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ*. 2007;85(11):867-72.

28. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis*. 2021.